OBJECTIVE: To 1) describe the distribution of patient global assessment (PtGA) scores of disease activity in patients with granulomatosis with polyangiitis (GPA; Wegener's), 2) explore the discordance between PtGA scores and physician global assessment (PhGA) scores of disease activity, and 3) explore whether PtGA scores during disease remission are associated with future disease relapse. METHODS: Data from the Wegener's Granulomatosis Etanercept Trial (WGET) were used. PtGA and PhGA scores were assessed on 100-mm visual analog scales (VAS). Presence of active disease was determined using the Birmingham Vasculitis Activity Score for WG (BVAS/WG), and remission was defined as a BVAS/WG score of 0. Disease relapse was defined as a BVAS/WG score of >0 after remission had been achieved. Discordance between PtGA and PhGA scores was defined as a difference of ≥20 points between the two measures. Mixed linear models were used in longitudinal analysis of PtGA scores. RESULTS: Data were obtained from 180 patients in the WGET cohort, seen at a total of 1,719 study visits. The mean ± SD PtGA and PhGA disease activity scores (on 100-mm VAS) at baseline were 64.2 ± 27.4 and 55.5 ± 23.4, respectively. PtGA-PhGA discordance occurred in 53% of patients at baseline, and this was inversely associated with newly diagnosed disease (as opposed to relapsing disease) at baseline (odds ratio 0.37, 95% confidence interval [95% CI] 0.20-0.68) but not with age, sex, or presence of renal or pulmonary disease. Patients were in disease remission during 62% of the study visits. The mean PtGA score during visits immediately prior to relapse was 4.52 points higher (95% CI 0.66-8.4) than that at other remission visits (P = 0.03). CONCLUSION: PtGA-PhGA discordance is common in GPA. A rise in the PtGA disease activity score during times defined by physicians as periods of remission is associated with subsequent occurrence of disease relapse. These findings support the addition of PtGA as an outcome measure for GPA.
OBJECTIVE: To 1) describe the distribution of patient global assessment (PtGA) scores of disease activity in patients with granulomatosis with polyangiitis (GPA; Wegener's), 2) explore the discordance between PtGA scores and physician global assessment (PhGA) scores of disease activity, and 3) explore whether PtGA scores during disease remission are associated with future disease relapse. METHODS: Data from the Wegener's Granulomatosis Etanercept Trial (WGET) were used. PtGA and PhGA scores were assessed on 100-mm visual analog scales (VAS). Presence of active disease was determined using the Birmingham Vasculitis Activity Score for WG (BVAS/WG), and remission was defined as a BVAS/WG score of 0. Disease relapse was defined as a BVAS/WG score of >0 after remission had been achieved. Discordance between PtGA and PhGA scores was defined as a difference of ≥20 points between the two measures. Mixed linear models were used in longitudinal analysis of PtGA scores. RESULTS: Data were obtained from 180 patients in the WGET cohort, seen at a total of 1,719 study visits. The mean ± SD PtGA and PhGA disease activity scores (on 100-mm VAS) at baseline were 64.2 ± 27.4 and 55.5 ± 23.4, respectively. PtGA-PhGA discordance occurred in 53% of patients at baseline, and this was inversely associated with newly diagnosed disease (as opposed to relapsing disease) at baseline (odds ratio 0.37, 95% confidence interval [95% CI] 0.20-0.68) but not with age, sex, or presence of renal or pulmonary disease. Patients were in disease remission during 62% of the study visits. The mean PtGA score during visits immediately prior to relapse was 4.52 points higher (95% CI 0.66-8.4) than that at other remission visits (P = 0.03). CONCLUSION: PtGA-PhGA discordance is common in GPA. A rise in the PtGA disease activity score during times defined by physicians as periods of remission is associated with subsequent occurrence of disease relapse. These findings support the addition of PtGA as an outcome measure for GPA.
Authors: Alvise Berti; Roscoe Warner; Kent Johnson; Divi Cornec; Darrell R Schroeder; Brian F Kabat; Carol A Langford; Cees G M Kallenberg; Philip Seo; Robert F Spiera; E William St Clair; Fernando C Fervenza; John H Stone; Paul A Monach; Ulrich Specks; Peter A Merkel Journal: J Autoimmun Date: 2019-07-15 Impact factor: 7.094
Authors: Gunnar Tomasson; John T Farrar; David Cuthbertson; Carol A McAlear; Susan Ashdown; Peter F Cronholm; Jill Dawson; Don Gebhart; Georgia Lanier; Raashid A Luqmani; Nataliya Milman; Jacqueline Peck; Joanna C Robson; Judy A Shea; Simon Carette; Nader Khalidi; Curry L Koening; Carol A Langford; Paul A Monach; Larry Moreland; Christian Pagnoux; Ulrich Specks; Antoine G Sreih; Steven R Ytterberg; Peter A Merkel Journal: J Rheumatol Date: 2019-03-01 Impact factor: 4.666
Authors: Kaitlin A Quinn; Sara Monti; Robin Christensen; David Jayne; Carol A Langford; Georgia E Lanier; Alfred Mahr; Christian Pagnoux; Beverley Shea; Maria Bjork Viðarsdóttir; Gunnar Tomasson; Peter A Merkel Journal: Semin Arthritis Rheum Date: 2022-04-28 Impact factor: 5.431
Authors: Sang-Won Lee; Do Young Kim; Sang Hoon Ahn; Yong-Beom Park; Kwang-Hyub Han; Jun Yong Park Journal: Rheumatol Int Date: 2018-05-12 Impact factor: 2.631
Authors: David T Selewski; Aliza Thompson; Sarrit Kovacs; Elektra J Papadopoulos; Noelle E Carlozzi; Howard Trachtman; Jonathan P Troost; Peter A Merkel; Debbie S Gipson Journal: Clin J Am Soc Nephrol Date: 2016-06-03 Impact factor: 8.237
Authors: Mollie N Schwartz; Casey A Rimland; Kaitlin A Quinn; Marcela A Ferrada; K Bates Gribbons; Joel S Rosenblum; Wendy Goodspeed; Elaine Novakovich; Peter C Grayson Journal: J Rheumatol Date: 2020-04-01 Impact factor: 4.666
Authors: Mark E McClure; James Wason; Seerapani Gopaluni; Joanna Tieu; Rona M Smith; David R Jayne; Rachel B Jones Journal: J Clin Rheumatol Date: 2019-08 Impact factor: 3.517